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The posttranslational modifications induced on PKC isozymes as result of their activation were investigated. Reciprocal immunoprecipitations
followed by Western blot analysis demonstrated that all PKC isozymes expressed in rat hepatocytes are modified by tyrosine nitration and tyrosine
phosphorylation in different ways upon exposure of cells to a direct PKC activator (TPA), or to an extracellular ligand known to activate PKC-
dependent pathways (epinephrine). Our data demonstrate for the first time that all PKC isozymes are also dynamically modified by O-linked β-N-
acetylglucosamine (O-GlcNAc); the presence of this modification was confirmed in part by FT-ICR mass spectrometry analysis. Interestingly, the
O-GlcNAc modified Ser or Thr were mapped at similar positions in several PKC isozymes. The biochemical meaning of these posttranslational
modifications was investigated for PKC alpha and delta. It was found that the PKC phosphorylation status of both isozymes in tyrosine and serine
residues seems to regulate directly the enzyme activity since catalytic inactivation correlate with dephosphorylation of Ser at the C-terminus
autophosphorylation sites of each PKC isozyme, and with an increase in the level of tyrosine phosphorylation. Whereas none of the other
posttranslational modifications showed per se a direct effect in PKC delta activity, increased tyrosine nitration and O-GlcNAc modifications
correlate negatively with PKCα activity.
© 2007 Elsevier B.V. All rights reserved.Keywords: PKC; Posttranslational modification; O-GlcNAc glycosylation; Tyrosine nitration; Tyrosine phosphorylation; Protein phosphorylation1. Introduction
Posttranslational modification represents a ubiquitous and
essential device for control of protein activity, localization, sta-
bility and protein–protein interaction. While reversible control
by phosphorylation/dephosphorylation is now firmly estab-
lished as a fundamental mechanism for regulating the function of
most members of the mammalian protein kinase superfamily,
less is known about the specific roles of other posttranslational
modifications.
Protein kinase C (PKC) plays key regulatory roles in major
signal transduction pathways controlling a wide range of bio-⁎ Corresponding author. Departamento de Bioquímica, Facultad de Medicina,
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doi:10.1016/j.bbamcr.2007.07.011logical responses including gene expression, cell morphology,
proliferation and differentiation [1]. The mechanism of activa-
tion of the PKC family has been investigated extensively.
Covalent posttranslational modification, namely serine/threo-
nine phosphorylation of PKC along with binding of PKC to the
lipid second messenger diacylglycerol are recognized as two
equally important mechanisms that regulate PKC activity [2].
PKC is processed by three phosphorylation events before it is
competent to respond to second messengers. Specifically, the
enzyme is first phosphorylated at the activation loop by another
kinase (PDK-1), followed by two ordered autophosphorylations
at the carboxyl terminus, one on a ‘turn’motif and the second on
a conserved ‘hydrophobic phosphorylation motif. Phosphoryla-
tions at these two C-terminal sites are believed to lock the
enzyme in a closed, catalytically-competent, stabilized, and
protease/phosphatase-resistant conformation [2,3].
On the other hand, posttranslational modification of tyro-
sine residues by phosphorylation has emerged as an important
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been reported that in response to H2O2, PKC isoforms can be
activated to various extents through tyrosine phosphorylation
exhibiting independence of lipid cofactors; it is, in a manner
unrelated to receptor-coupled hydrolysis of inositol phospho-
lipids [2,4].
Tyrosine nitration of proteins is also a selective process with
respect to both the proteins and the specific protein tyrosine
residues that can undergo this posttranslational modification [5].
It has been reported that nitric oxide (NO) induces peroxynitrite-
mediated tyrosine nitration of PKCε in rabbit cardiomyocytes in
vitro, and in vivo in the rabbit myocardium preconditioned with
NO donors [6]. Furthermore, nitration of PKCε facilitates its
interaction with the selective anchoring protein RACK2 and
promotes translocation and activation of PKCε [6].
N-acetylglucosamine O-linked (O-GlcNAc) to serines and
threonines of cytosolic and nuclear proteins is another abundant
reversible posttranslational modification found in all higher eu-
karyotes [7]. About 100 mammalian proteins have been identified
so far that carry this modification. They include transcription
factors, signaling components, and metabolic enzymes [7,8].
While the modification has been known for almost 20 years,
functions for the monosaccharide modification are just now emer-
ging . It has been reported that increased flux through hexosamine
biosynthetic pathway affects the activity and translocation of
certain PKC isoforms [9]. In this work, we present evidence for
the first time that conventional, novel and atypical PKC isozymes
are all post-translationally modified by O-GlcNAc. Additionally,
it was demonstrated here that PKC posttranslational modifications
other than serine/threonine or tyrosine phosphorylation such
as tyrosine nitration seem to be also a general modification pre-
sent in all PKC isozymes. We have found that these modi-
fications are dynamically changed as result of PKC activation
in vivo. The biochemical meaning of these posttranslational modi-
fications for PKC alpha and PKCδ was investigated. Our results
indicate that PKC phosphorylation status, both in serine and
tyrosine residues, seems to regulate directly the kinase activity
of both isozymes whereas tyrosine nitration and O-GlcNAc af-
fect negatively PKCα activity but do not affect per se PKCδ
activity.
2. Materials and methods
2.1. Reactives and antibodies
Antibodies against PKC isoforms were from the following sources: Murine
monoclonal antibodies to PKC isoenzymes and anti-phosphotyrosine (clone
4G10) were purchased from Upstate Biotechnology Inc. Isozyme-specific
polyclonal antibodies against the C-terminus of PKC isozymes were obtained
from Santa Cruz Biotechnology Inc. Phospho site-specific PKC alpha antibody
and nitro-Tyrosine polyclonal antibody were from Cell Signaling Technology.
O-linked N-acetylglucosamine antibodies were purchased from Affinity
Bioreagents Inc. (catalog number MA1-076 and MA1-072). Goat anti-mouse
and anti-rabbit IgG-alkaline phosphatase conjugates were from Bio-Rad.
Phorbol 12-myristate 13-acetate (PMA), Histone H1-IIIS, phosphatidylserine,
Triton X-100, 1,2-diolein, 3-Nitro-L-Tyrosine and N-acetyl-D-glucosamine
were from Sigma. Protein A-sepharose and bisindolylmaleimide I were from
Calbiochem, DEAE-cellulose (DE-52) was from Whatman. [γ-32P]ATP
(6000 Ci/mmol) was from DuPont-NEN. All other chemicals were reagent
grade.2.2. Isolation of rat hepatocytes
Male Wistar rats (200–250 g) fed ad libitum were used. Hepatocytes were
isolated by the collagenase perfusion method described by Berry and Friend
[10].
2.3. Immunoprecipitation
Freshly isolated rat hepatocytes were incubated in the absence (vehicle) or
presence of 1 μM TPA or 10 μM epinephrine plus propranolol for 5 min. Cells
were washed and homogenized in ice cold buffer containing 20 mM Tris–HCl
pH 7.5, 10 mM EGTA, 2 mM EDTA, 0.5% Triton X-100 and a mixture of
protease inhibitors (100 mM PMSF, 0.1 mg/ml trypsin inhibitor, 10 μg/ml
leupeptin) and protein phosphatase inhibitors (10 mM β-glycerophosphate,
1 mM Na3VO4, 11 mM NaF, 10 mM sodium pyrophosphate and 0.2 mg/ml
phosphoserine). The protein concentration in cell extracts was measured
according to Bio-Rad Laboratories, Inc. detergent-compatible protein assay.
Aliquots of cell extracts (1 mg/ml) were incubated overnight at 4 °C with 1 μg/ml
of primary antibody (isozyme-specific PKC antibody, anti phospho-Tyrosine,
anti nitro-Tirosine or anti Ser/Thr-GlcNAc) with gentle shaking. Then, 20 μl
protein A-sepharose (30%, Calbiochem) were added and incubation continued
for 2 h. Immune complexes were then washed three times with buffer A (50 mM
Tris–HCl, 0.6 M NaCl, 1% Triton X-100, 0.5% Nonidet P-40, pH 8.3)
supplemented with 0.1 mg/ml trypsin inhibitor and 1 mM PMSF and once with
buffer B (20 mM Tris–HCl pH 7.5, 0.15 M NaCl) containing protease and
phosphatase inhibitors.
2.4. Western blotting
Samples of protein (100 μg) were separated by 10% SDS-PAGE followed by
electrophoretic transfer to PVDF membranes. When probing for phosphoryla-
tion sites, skimmed milk powder was substituted by 3% (w/v) BSA for mem-
brane blocking. Detection was achieved using the Supersignal kit (Pierce) with a
horseradish peroxidase-conjugated second antibody. In all experiments,
immunoblots were stripped by incubation in 100 mM 2-mercaptoethanol, 2%
SDS and 63 mM Tris–HCl, pH 6.7 at 60 °C for 1 h and reprobed with the other
primary antibody (anti-PKC isozyme-specific antibody). These blots were
developed in the same way in order to serve as loading and specificity controls.
2.5. Purification of PKC
PKC was purified as described previously [11]. In brief, hepatocytes were
homogenized in ice-cold buffer (20 mM Tris–HCl, pH 7.5, 10 mM EGTA,
2 mM EDTA, 0.5% Triton X-100, 50 mM 2-mercaptoethanol, 1 mM PMSF,
10 μg/ml leupeptin and 0.1 mg/ml trypsin inhibitor), in the presence of
phosphatase inhibitors (10 mM β-glycerophosphate, 1 mM Na3VO4, 11 mM
NaF, 10 mM sodium pyrophosphate and 0.2 mg/ml phosphoserine) and
incubated at 4 °C for 30 min. Homogenates were subjected to centrifugation at
28,000×g for 20 min. Portions of the supernatant were applied to DEAE-
cellulose columns that had been equilibrated with column buffer (20 mM Tris–
HCl pH 7.5 and 50 mM 2-mercaptoethanol) at 4 °C. After washing with column
buffer, PKC 1 was eluted first with column buffer containing 0.08 M NaCl,
2 mM EDTA and 0.1 mg/ml trypsin inhibitor, and then PKC 2 with this buffer
containing 0.25 M NaCl. The eluates were concentrated with an Amicon device
(YM-30 membrane) and used as starting material for the immunoprecipitation
studies.
PKC to be analyzed by mass spectrometry was further purified to
homogeneity by phenyl-sepharose column chromatography followed by zonal
size-exclusion chromatography. Eluates obtained from DEAE cellulose were
adjusted with NaCl until reach 1.5 M concentration and applied to phenyl
sepharose columns that had been equilibrated with buffer A (20 mM Tris–HCl
pH 7.5, 50 mM 2-mercaptoethanol, 1.5 M NaCl, 0.5 mM EDTA and 0.5 mM
EGTA). After washing with buffer A, PKC was eluted with the same buffer but
without NaCl, concentrated and applied to a Beckman high performance liquid
chromatography (HPLC) system with a 7.5×300 mm Superdex 200 column.
The mobile phase contained 1 mM EDTA, 150 mM NaCl, and 100 mM sodium
phosphate (pH 7.0). With this purification protocol, all PKC isoforms present in
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Coomassie blue staining after 10% SDS-PAGE, Western blot analysis and
activity assay. Excised Coomassie blue stained gel bands corresponding to PKC
purified from control (C-PKC) or TPA-treated cells (T-PKC) and blank (without
protein) were initially destained followed by ingel tryptic digestion. Peptides
were extracted for FTMS analysis.
2.6. Fourier Transform Ion Cyclotron Resonance (FT-ICR) mass
spectrometry
The presence of posttranslational modifications (phosphorylation and O-
GlcNAc) from control (C-PKC) or from TPA-treated cells (T-PKC) samples was
examined by FTMS analysis obtained from the Mass Spectrometry and
Proteomics services offered by the WM Keck Foundation Biotechnology
Resource Laboratory at Yale University. The mass spectral data were obtained
from a Bruker Daltonics (Billerica, MA) 9.4 T Apex-Qe Hybrid Qq-Fourier
Transform Ion Cyclotron Resonance (FT-ICR) mass spectrometer. The samples
(C-PKC or T-PKC) were directly infused into the FT-ICRMS by nanoESI with aFig. 1. Analysis of tyrosine phosphorylation changes induced on PKC isozymes in res
rat hepatocytes were incubated 5 min in the absence (C) or presence of 1 μM TPA
(A) PKC isozymes were immunoprecipitated from cell lysates of rat hepatocytes cont
Western blotting. Immunoblots were stripped, reprobed with anti-PKC isozyme-spe
graph corresponding to the quantitative scans of several independent experiments (ch
shown. Values plotted are means±S.E.M. of four immunoprecipitation experiment
immunoprecipitated in the same way as in panel A, using antiphosphotyrosine-specif
PKC isozyme-specific antibodies. Results shown are representative of at least four i30-μm id fuse silica tip (New Objective, Inc.) at a 15 μL/h flow rate. The nESI
tip was grounded and a 1600 V potential was applied on the glass capillary
endcap. The instrument (running Compass Software with APEX control
acquisition component (v.1.2) is setup to acquire single fid (512 K) data and with
a mass range (m/z) from 500 to 3500. Quadrupole isolations of peak of interest
were subsequently fragmented by either Collision Induced Dissociation (CID),
InfraRed MultiPhoton Dissociation (IRMPD), or Electron Captured Dissocia-
tion (ECD). Bruker Daltonics DataAnalysis software (v. 3.4) was used to
analyze the data. Collected time transient data were Fourier transformed,
magnitude calculations made to generate m/z mass spectrum, then deconvoluted
to determine monoisotopic peptide masses. Peptide searches were analyzed with
GPMAW (General Protein/Mass Analysis for Windows, Lighthouse Data)
software to determine the various modifications.
2.7. PKC immune complex kinase assay
This was performed as described in [12]. Briefly, aliquots of 1 ml of partially
purified and concentrated PKC (1 mg/ml) in the presence of phosphataseponse to acute TPA or epinephrine treatment of rat hepatocytes. Freshly isolated
(T) or 10 μM epinephrine plus 10 μM β-adrenergic antagonist propranolol (E).
aining 1 mg of total cellular protein and tyrosine phosphorylation determined by
cific antibody and developed in the same way. A representative blot with a bar
ange in PTM normalized to PKC protein and then expressed as % of control) is
s using different cell preparations. (B) Tyrosine phosphorylated proteins were
ic antibody (4G10) and immunoprecipitates analyzed by Western blot using anti-
mmunoprecipitation experiments using different cell preparations.
Fig. 2. Analysis of TPA or epinephrine-induced tyrosine nitration on rat hepatocytes PKC isozymes. Freshly isolated rat hepatocytes were incubated 5 min in the
absence (C) or presence of 1 μM TPA (T) or 10 μM epinephrine plus 10 μM β-adrenergic antagonist propranolol (E). (A) PKC isozymes were immunoprecipitated
from cell lysates of rat hepatocytes containing 1 mg of total cellular protein and tyrosine nitration determined by Western blotting. Immunoblots were stripped,
reprobed with anti-PKC isozyme-specific antibody and developed in the same way. A representative blot with a bar graph corresponding to the quantitative scans of
several independent experiments (change in PTM normalized to PKC protein and then expressed as % of control) is shown. Values plotted are means±S.E.M. of four
immunoprecipitation experiments using different cell preparations. (B) Tyrosine nitrated proteins were immunoprecipitated in the same way as in panel A, using nitro-
tyrosine polyclonal antibody highly specific for nitrated Tyr. Immunoprecipitates were analyzed by Western blot using anti-PKC isozyme-specific antibodies. Results
shown are representative of at least four independent experiments. (C) Cellular extracts from TPA or epinephrine-treated rat hepatocytes were immunoprecipitated with
anti-PKC α and anti-PKCε antibodies and then subjected to Western blot analysis with anti-nitrotyrosine antibody in the absence or presence of 10 mM of free nitro-
tyrosine to confirm the specificity of the antibody for nitro-tyrosine. Membranes were stripped and reprobed with anti PKC α and anti-PKCε antibodies. This is a
representative blot of three independent experiments. (D) Freshly isolated rat hepatocytes were incubated for 15 min in the absence or presence of 1 mMMEG; then,
1 μM TPAwas added and the incubation continued another 5 min. PKCα was immunoprecipitated and analyzed by Western blot with anti-nitrotyrosine antibodies.
The membrane was stripped and re-probed with anti PKCα. Results shown are representative of three independent experiments.
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sodium pyrophosphate and 0.2 mg/ml phospho-serine) and in the absence of 2-
mercaptoethanol were incubated at 4 °C with 1 μg/ml of isozyme-specific PKCFig. 3. Analysis of TPA or epinephrine-induced O-GlcNAc glycosylation on rat hepa
the absence (C) or presence of 1 μMTPA (T) or 10 μM epinephrine plus 10 μM β-adr
from cell lysates of rat hepatocytes containing 1 mg of total cellular protein and ana
with anti-PKC isozyme-specific antibody and developed in the same way. A represe
independent experiments (change in PTM normalized to PKC protein and then ex
immunoprecipitation experiments using different cell preparations. (B) O-GlcNAc-m
monoclonal antibodies that recognize O-GlcNAc glycosylated proteins. Immunop
antibodies. Results shown are representative of at least five independent experimen
immunoprecipitated with anti-PKC α and anti-PKCβ antibodies and then subjected t
of 0.2 M of free N-acetyl-D-glucosamine to confirm the specificity of the antibody for
anti-PKCβ antibodies. This is a representative blot of three independent experimentantibody for 1 h with gentle shaking. Then, 20 μl protein A-sepharose (30%,
Calbiochem) were added and incubation continued for 1 h. Immune complexes
were then washed three times with buffer A (50 mM Tris–HCl, 0.6 M NaCl, 1%tocytes PKC isozymes. Freshly isolated rat hepatocytes were incubated 5 min in
energic antagonist propranolol (E). (A) PKC isozymes were immunoprecipitated
lyzed for O-GlcNAc by Western blotting. Immunoblots were stripped, reprobed
ntative blot with a bar graph corresponding to the quantitative scans of several
pressed as % of control) is shown. Values plotted are means±S.E.M. of five
odified proteins were immunoprecipitated in the same way as in panel A, using
recipitates were analyzed by Western blot using anti-PKC isozyme-specific
ts. (C) Cellular extracts from TPA or epinephrine-treated rat hepatocytes were
o Western blot analysis with anti O-GlcNAc antibody in the absence or presence
O-linked GlcNAc. Membranes were stripped and reprobed with anti PKC α and
s.
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inhibitor, 1 mM PMSF and phosphatase inhibitors and once with kinase buffer
(20 mM Tris–HCl pH 7.5, 10 mM MgCl2, 0.5 mM CaCl2, 50 mM 2-
mercaptoethanol) supplemented with protease and phosphatase inhibitors.
Kinase activity was initiated by resuspending the immunoprecipitates in 50 μl of
assay mixture: kinase buffer plus 20 μg/ml phosphatidylserine, 0.8 μg/ml 1,2-
diolein, 10 μM [γ-32P]ATP (6000 Ci/mmol) and 200 μg/ml of protein substrate
(histone H1-IIIS). Reactions were allowed to proceed for 20 min at 30°C, ended
by the addition of 50 μl of SDS-PAGE sample buffer, boiled for 5 min and
analyzed by 12.5% SDS-PAGE and autoradiography. Data were quantified by
densitometric analysis performed both in Coomassie-stained gels and the
corresponding autoradiographies. The ratio of 32P-labeled protein/dyed protein
represents the total specific phosphorylation.
3. Results
3.1. All PKC isozymes expressed in rat hepatocytes
are dynamically modified by tyrosine phosphorylation as
result of PKC activation
Rat hepatocytes express several PKC isoenzymes (α, βII, δ,
ε, θ, μ and ζ), which are activated and differentially down-
regulated during acute (5 min) TPA treatment [11]. ActivationFig. 4. Results of FT-ICR mass spectrometry analysis. (A) Comparison of the entire F
(B) Positive mode MS spectrum of T-PKC with zoom insets showing peptides that a
spectra of peptide at m/z 1071 (+3). The figure shows the intact (modified) mass of th
subsequent fragmentation of the peptide shows several y-ions fragments (as indicat
modification. Since the identified peptide only contains one serine (no threonine) in it
of the serine at position S418.of PKC is generally correlated with its serine–theonine phos-
phorylation and translocation to cell membranes [for review, see
Ref 2], but it has been reported also that other posttranslational
modifications (PTM) like tyrosine phosphorylation or tyrosine
nitration may modulate PKC activity [4,6]. To elucidate if these
modifications are induced on PKC isozymes as result of
PKC activation, we studied the effect of epinephrine on PKC
isoforms via activation of α1-adrenergic receptors in compar-
ison with acute TPA treatment. Freshly isolated rat hepatocytes
were incubated for 5 min in the absence (vehicle) or presence
of 1 μM TPA or 10 μM epinephrine plus 10 μM propranolol
(β-adrenergic antagonist). PKC isozymes were immunopreci-
pitated from cell extracts and posttranslational modifications
produced on them analyzed by Western blotting. Fig. 1A shows
a bar graph of quantitative scans of several experiments (change
in PTM normalized to protein and then expressed as % of
control) and displays a representative blot of them. It can be
observed that in basal state all PKC isoforms appeared tyrosine-
phosphorylated. When rat hepatocytes were stimulated with
TPA or epinephrine, all of them were modified on their tyro-
sine phosphorylation content. No immunoreactive bands wereT-ICR mass spectra of C-PKC and T-PKC samples directly infused by nanoESI.
ppeared only in T-PKC and not in C-PKC samples. (C) Deconvoluted MS/MS
e peptide identified as 3212 Da from the epsilon PKC protein. The isolation and
ed by 90° angled arrow, and labeled on the spectrum) containing the HexNAc
, the only possible location for the O-linked glycosylation is then deduced to that
Fig. 4 (continued ).
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(data not shown). Conventional βII and novel ε and θ PKC
isozymes increased their tyrosine phosphorylation content as
result of TPA or epinephrine treatment in comparison with
control unstimulated cells (Fig. 1 panel A). PKCδ and ζ were
diminished in their tyrosine phosphorylation level either by TPA
or epinephrine treatment, whereas these agents induced opposite
effects in tyrosine phosphorylation of PKCα. Reverse immuno-
precipitations, i.e., using anti-phosphotyrosine antibody (4G10,
Upstate Biotechnology Inc) and developed with the respective
anti-PKC isozyme antibodies, gave the same results with total
cell extracts obtained from TPA-treated hepatocytes (Fig. 1 panel
B), confirming therefore the changes in tyrosine phosphorylation
induced by TPA.
3.2. All PKC isozymes expressed in rat hepatocytes
are dynamically modified by tyrosine nitration which
change differentially in response to TPA or
epinephrine treatment of cells
It has been reported that posttranslational modification of
PKCε by nitric oxide (NO)-mediated tyrosine nitration,
promotes its translocation and activation both in vitro and invivo in the rabbit myocardium [6]. Unexpectedly, when PKC
isozymes immunoprecipitated from freshly isolated rat hepato-
cytes were analyzed with anti-nitrotyrosine by Western blotting,
it was found that all PKC isoforms have this modification in
unstimulated hepatocytes (Fig. 2 panels A and B). No immu-
noreactive bands were observed in the precipitates obtained
with non-immune serum (data not shown). Interestingly,
stimulation of cells with 1 μM TPA 5 min induced an increase
in nitrotyrosine of α, θ and ζ PKC isozymes, and a decrease
in nitrotyrosine content in PKCδ and ε isozymes (see bar graph
of quantitative data in Figs. 2A and B). These results were
confirmed by immunoprecipitating nitrotyrosine-modified pro-
teins (with polyclonal antibody obtained from Cell Signaling
Technology Inc) from cells treated with TPA for 5 min followed
by analysis of the immunoprecipitates with anti-PKC isozyme-
specific antibodies (Fig. 2 panel B). Epinephrine treatment
(5 min) produced the same effect in PKCζ as TPA, increasing its
nitrotyrosine levels in comparison with control untreated cells,
but induced a decrease in nitrotyrosine content of PKC β and δ
isoforms (Fig. 2 panel A). To verify the specificity of the
antibody, cellular extracts from TPA or epinephrine-treated rat
hepatocytes were immunoprecipitated with anti-PKC α and
anti-PKCε antibodies and then subjected to Western blot
Fig. 4 (continued ).
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significant increase in nitrotyrosine level in the band
corresponding to PKCα (lower band in Fig. 2C) and a decrease
in nitrotyrosine content of PKCε (upper band in Fig. 2C) as
result of TPA treatment. However, when Western blot analysis
for nitrotyrosine was performed in the presence of 10 mM of
free 3-Nitro-L-tyrosine, the bands corresponding to nitrotyr-
osine-containing proteins almost disappeared (Fig. 2 panel C).
In addition, when WB analysis for nitrotyrosine was carried out
for a recombinant GST protein obtained from bacterial lysates,
no band was observed (data not shown).
It has been reported that several reactions mediate protein
nitration, and all predominantly depend on nitric oxide (·NO)
and nitrite-dependent formation of nitrogen dioxide [5]. In order
to determine the mechanism underlying the PKC nitration, we
used mercaptoethylguanidine (MEG), a selective cell permeable
inhibitor of inducible nitric oxide synthase (iNOS) and a pe-
roxynitrite scavenger. Freshly isolated rat hepatocytes were
preincubated for 15 min in the absence or presence of 1 mM
MEG; after this incubation period, 1 μMTPAwas added and the
incubation continued for another 5 min. PKCα was then immu-
noprecipitated from control or TPA treated cells, and results
presented in Fig. 2 panel D showed that MEG pre-treatment
abolished the increased in tyrosine nitration induced by TPA.
Taken together, these results indicate that Tyr nitration is a
posttranslational modification generally present in PKC iso-
zymes, that it is associated to NO production upon exposure ofcells to a direct PKC activator (TPA) or to an extracellular
ligand that activate PKC-dependent pathways (epinephrine).
3.3. O-linked N-acetylglucosamine modification are induced in
PKC isozymes by TPA or epinephrine as result of their activation
O-linked β-N-acetylglucosamine (O-GlcNAc) is a mono-
saccharide modification abundant on serine and threonine
residues of many nucleocytoplasmic proteins [7]. It appears to
be a key modification of proteins that regulates multiple cellular
processes ranging from signaling to transcription to protein
synthesis [7,8]. Although about 100 mammalian proteins have
been identified to date that carry this modification, it has not
been reported yet for PKC. Using antibodies that recognizes O-
linked GlcNAc in proteins (Affinity Bioreagents Inc), we
examined the presence of this modification on PKC isozymes
immunoprecipitated from TPA or epinephrine stimulated rat
hepatocytes. As it can be observed in Fig. 3 panels A and B, all
PKC isoforms expressed in these cells contain O-GlcNAc in
basal, non stimulated conditions. Upon acute TPA stimulation
of hepatocytes, O-GlcNAc levels on all PKC isoforms, except
θ, increased with respect to those observed in control un-
stimulated cells (Fig. 3). These results were also obtained in the
reciprocal immunoprecipitations, as it can be seen in Fig. 3
panel B but no immunoreactive bands were observed in the
precipitates obtained with non-immune serum (data not show).
Remarkably, epinephrine induced an increase in the O-GlcNAc
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GlcNAc content of the other PKC isozymes (see Fig. 3 panels A
and B). Importantly, the specificity of the anti-OGlcNAc
antibody used was confirmed when the Western blot analysis
were performed in the presence of an excess of free N-acetyl-D-
glucosamine, as it can be seen in Fig. 3 panel C. Cellular
extracts from TPA or epinephrine-treated rat hepatocytes were
immunoprecipitated with anti-PKC α and anti-PKCβ anti-
bodies and then subjected to Western blot analysis with anti O-
GlcNAc antibody. We observed a TPA or epinephrine-induced
increase in the GlcNAc level in the band corresponding to
PKCα and β (same molecular weight) in Fig. 3C, that greatly
diminished when theWestern blot analysis was performed in the
presence of 0.2 M free N-acetyl-D-glucosamine. In addition,
when WB analysis for O-GlcNAc was carried out for a
recombinant GST protein obtained from Escherichia coli, no
band was observed (data not shown).
3.4. Identification and mapping of GlcNAc bound to
serine/threonine in PKC isozymes by mass spectrometry
Because the finding of O-GlcNAc bound to PKC was novel,
we considered it important to convincingly demonstrate the
presence of this modification in PKC by mass spectrometry and
do not rely only on a Western blot approach. PKC isozymes
were purified to homogeneity and samples from control
untreated rat hepatocytes (C-PKC) or from TPA-treated cells
(T-PKC, 1 μM for 5 min) were prepared for FTMS analysis
according to the Keck Foundation instructions, as described in
Materials and methods. With the purification protocol em-
ployed, all PKC isoforms present in rat hepatocytes co-purified.
C-PKC vs. T-PKC samples were analyzed to compare “parent”
protein/peptide that, according to our data, already has the O-
GlcNAc modification, with the protein/peptide obtained with an
expected increase in O-GlcNAc content as result of TPA treat-
ment. Samples were tryptic digested and the extracted peptide
mixture from the gel was dried down, reconstituted in 0.1%
TFA, concentrated and desalted by RP C-18 ZipTip and run by
direct infusion nanoelectrospray (nESI) FT-ICR mass spec-
trometry to obtained accurate mass of all peptides. The high
mass accuracy of FT-ICR (∼1–2 ppm with external calibration)
provides the confidence for the identification ( N95% prob-
ability) of modified peptides based on the monoisotopic peptide
mass. Fig. 4 (panel A) shows the comparison of the entire
spectra of C-PKC and T-PKC peptides and panel B shows the
positive mode MS spectrum of T-PKC, with zoom insets show-
ing regions where peptides differed from that of C-PKC. As it
can be observed, there were clear differences between these two
samples, reflected in the fact that 48 peaks out of 89 identified
(shown in Table 1), were unique peaks observed in the T-PKC
and not in the C-PKC spectrum. To determine what were these
differences, the broadband T-PKC peaks were analyzed with
GPMAW software (http://wellcome.to/gpmaw) using a data-
base generated with the sequence for the various PKC isoforms.
The search was carried out with both possible phosphorylation
(80 Da mass) and GlcNAc (HexNAc) modification (203 Da
mass) on S and T with possible up to 4 modifications. Thesearch results with the peptide assignments of T-PKC peaks are
presented in Tables 1 and 2. As it can be seen, several masses
matched up with the predicted modification on the PKC
isozymes sequences (a mass increase of 203 Da in most cases,
except one case with double modification in the same peptide).
Confirmation of assignments with the modification was
achieved by isolating some modified peptides and subjecting
them to MS/MS. In spite we only could to confirm the
assignments partially, due to the fact that isolated peptides did
not fragment well by MS/MS analysis and the fragments
obtained did not loss the HexNAc, this approach validated the
results obtained by immunoprecipitation and Western blot ana-
lysis. For example, the isolation and subsequent fragmentation
by CID (Collision Induced Dissociation) and/or ECD/IRMPD
(Electron Captured Dissociation/InfraRed MultiPhoton Disso-
ciation) of the T-PKC spectrum component AP, corresponding
to peptide with a monoisotopic mass of 3212.627 Da, confirmed
that it belonged to PKC epsilon and that the GlcNAc
modification is in serine (S 418), as shown in Fig. 4 panel C
with its corresponding Table 3. In addition, it can be seen that it
was found that PKC gamma is also expressed in rat hepatocytes.
In this respect, although it had been reported that trout
hepatocytes express this isoform [13], until now, its expression
in rat hepatocytes was frequently reported below detection
limits. It is important to take into account that antibodies used
for its detection are frequently directed against the carboxyl
terminus that, as it can be observed in Table 2, it appeared in
PKC gamma double modified by O-GlcNAc. So, it is possible
that the antibodies do not recognize efficiently the O-GlcNAc
modified enzyme. Using a mixture of antibodies against PKC
gamma, we could also confirmed by Western blot its expression
in rat hepatocytes (data not shown), and its presence in the O-
GlcNAc immunoprecipitates obtained from rat hepatocytes
treated with TPA, as shown in Fig. 3 panel B. The general
analysis of the collected data presented in Table 2, showed
several interesting things. Firstly, it is noteworthy that O-
GlcNAc modification appeared at similar positions in all PKC
isoforms, like the middle part of the molecule. Secondly, in spite
the % of sequence identity varied between PKC isoforms, the
O-GlcNAc-modification was found in different peptides with
similar sequences shared by various isozymes, as indicated in the
“Observations” part of Table 2, and Thirdly, in many instances,
marked in red in Table 2, the probably modified residue found,
agree with the predicted O-GlcNAc potential sites (http://www.
cbs.dtu.dk/services/YinOYang/), with YinOYang predictions (S/
T residues that can be either phosphorylated or modified by O-
GlcNAc) or with a predicted ‘priming site’ (T 710 at ‘turn motif’
of PKC epsilon).
With respect to the analysis of the peptides modified by
phosphorylation, the results obtained did not allow us to
discriminate between Ser/Thr or tyrosine phosphorylation,
because in most cases, phosphorylated peptides contained
both Ser/Thr and Tyr (see Table 2). In only one case, it seems
that tyrosine was the modified residue: the PKC epsilon peptide
DRLFFVMEYVNGGDLMFQIQRSR, with an isotopic mass
of 2901 Da. This sequence, present in all PKC isoforms with a
high grade of conservation, contains invariably in most of them
Table 1
Search results of broadband T-PKC peaks (analyzed with GPMAW software) obtained from FT-ICR Mass spectrometry
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The search results showing the modifications observed and their possible location site at each PKC isoform are presented. There are two columns, “search mass” and “found mass”. The “search mass” is the mass that
was obtained from the FT-ICR analysis performed with our sample and that was input into GPMAW to search against the sequences in the protein database (of various PKC isoforms). The “found mass” is the mass
of the “predicted” unmodified peptide from the search results. Marked in bold are data corresponding to TPA unique peaks and marked in red are residues that matched with predicted ones in YinO-Yang website or
with predicted ‘priming sites’. Highlighted in blue are data corresponding to PKC epsilon 3212.627 Da peptide, whose MS/MS details are shown in Figure 4C.
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Table 3
MS/MS fragmentation data obtained from GPMAW corresponding to MH+
3212.627 peptide RLGLDEFNFIKVLGKGSFGKVMLAELK
Sequence
a b' c'' x' y'' z
129.11 158.12 176.15 1 Arg 27 _ _ _
242.2 271.2 289.23 2 Leu 26 3081.65 3056.68 3037.63
299.22 328.22 346.26 3 Gly 25 2968.56 2943.59 2924.55
412.3 441.31 459.34 4 Leu 24 2911.54 2886.57 2867.53
527.53 556.33 574.37 5 Asp 23 2798.46 2773.49 2754.44
656.37 685.38 703.41 6 Glu 22 2683.43 2658.46 2639.42
803.44 832.44 850.48 7 Phe 21 2554.39 2529.42 2510.37
917.48 946.47 964.52 8 Asn 20 2407.32 2382.35 2363.31
1064.55 1093.56 1111.59 9 Phe 19 2293.28 2268.3 2249.26
1177.64 1206.64 1224.67 10 Ile 18 2146.21 2121.24 2102.2
1305.73 1334.73 1352.77 11 Lys 17 2033.12 2008.15 1989.11
1404.8 1433.8 1451.84 12 Val 16 1905.03 1880.06 1861.02
1517.88 1546.89 1564.92 13 Leu 15 1805.96 1780.99 1761.95
1574.91 1603.91 1621.94 14 Gly 14 1692.88 1667.9 1648.86
1703 1732 1750.04 15 Lys 13 1635.86 1610.88 1591.84
1760.02 1789.02 1807.06 16 Gly 12 1507.76 1482.79 1463.75
2050.13 2079.14 2097.17 17 Ser 11 1450.74 1425.77 1406.73
2197.2 2226.2 2244.24 18 Phe 10 1160.63 1135.66 1116.61
2254.22 2283.23 2301.26 19 Gly 9 1013.56 988.59 969.55
2382.32 2411.32 2429.36 20 Lys 8 956.54 931.57 912.52
2481.39 2510.39 2528.42 21 Val 7 828.44 803.47 784.43
2612.43 2641.43 2659.46 22 Met 6 729.37 704.4 685.36
2725.51 2754.51 2772.55 23 Leu 5 598.33 573.36 554.32
2796.55 2825.55 2843.59 24 Ala 4 485.25 460.28 441.24
2925.59 2954.59 2972.63 25 Glu 3 414.21 389.24 370.2
3038.68 3067.68 3085.71 26 Leu 2 285.17 860.2 241.16
_ _ _ 27 Lys 1 172.09 147.11 128.07
Modifications: Ser 17 O-glycosyl/.
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PKC theta.
Taken together all these results convincingly support the
presence of O-GlcNAc bound to Ser/Thr in PKC isozymes.
3.5. Biochemicalmeaning of PKCposttranslationalmodifications
We have previously reported that total PKC activity from rat
hepatocytes can be separated in two subpopulations of isozymes
using DEAE-cellulose chromatography that we named PKC 1
and PKC 2 [11]. We also reported that some isoforms, as PKCα
and PKCδ, are present in both peaks of activity exhibiting
substantial differences in their catalytic properties as result of
phorbol ester treatment of cells [11]. These data suggested that
some isoforms, like α and δ, can be separated into different
peaks due to the presence of different posttranslational
modifications (PTMs) in these isozymes. In order to examine
this possibility, freshly isolated rat hepatocytes were incubated
for 5 min in the absence or presence of 1 μM TPA or 10 μM
epinephrine plus propranolol. The cells were washed, lysed and
PKC was partially purified by DEAE-cellulose chromatography
to produce the two peaks of PKC activity (peak 1 and peak 2) as
described in Materials and methods. PKCα and PKCδ were
then immunoprecipitated from each peak and analyzed for
activity and for the presence of PTMs. Fig. 5 panel A shows the
specificity of the activity assay using PKC isozyme-specificimmune complexes obtained from pooled PKC 1 and PKC 2
peaks. As it can be observed, the phosphorylation of histone H1
was markedly diminished in the presence of 1 μM of the
selective PKC inhibitor bisindolylmaleimide I (H+I), therefore
establishing that the phosphorylation of histone H1 was
mediated by PKC. Remarkably, TPA induced a selective loss
of activity in only one peak of each isozyme in comparison with
control untreated cells (Fig. 5 panel B). That is, TPA induced a
severe decrease of activity of PKCα eluted from peak 1 (eluting
at 80 mM Na Cl), while not affecting the activity of PKCα
eluted from peak 2 (eluting at 250 mM NaCl). The opposite
effect was produced by TPA in PKCδ (Fig. 5 panel B). In
response to epinephrine treatment, neither the activity of PKCα
nor the activity of PKCδ eluted from any peak was negatively
affected and the activity of PKCα in peak 2 was improved with
respect to control unstimulated cells (Fig. 5 panel B). As
mentioned before, until now, it has reported only the bio-
chemical meaning of both serine/threonine and tyrosine
phosphorylation on PKC isozymes and the activation by tyro-
sine nitration of PKCε. We examined therefore the phosphor-
ylation status of PKC α and δ isozymes. In this respect, it is well
known that there are three conserved phosphorylation sites in
PKC isoforms termed ‘priming sites’ that regulate the
maturation, signalling and down-regulation of PKC [2,3,14].
The corresponding aminoacids in the α isoform are Thr 497 at
the activation loop, which is a trans-phosphorylation site, and
Thr 638 (at ‘turn motif’) and Ser 657 (at ‘hydrophobic motif’) at
the C terminus representing autophosphorylation sites. It has
been reported that when PKCα is phosphorylated in these three
priming sites, it has a higher specific activity than when un-
phosphorylated [15,16]. In the case of PKCδ, the corresponding
residues are Thr 505 at the activation loop, and Ser 676 and Ser
695 at C-terminus. Using ‘phosphosite-specific’ antibodies
(Cell Signaling Inc) for the Western blot analysis of PKCα and
PKCδ immunoprecipitates corresponding to each peak of
activity, we found that there was a direct correlation between
the phosphorylation state at ‘hydrophobic motif’ of each
isozyme with the isozyme activity (Fig. 5 panels B and C).
Accordingly, PKCα was dephosphorylated as result of TPA
treatment only in peak 1, that displayed low PKCα activity in
response to TPA, but remained phosphorylated, even more than
control, in peak 2, that displayed high specific activity as result
of TPA treatment. These results correlated also directly for
PKCδ activity (Fig. 5 B and C), since it appeared depho-
sphorylated at Ser 662 when its activity was diminished
(peak 2) with respect to control, but appeared phosphorylated
when its activity was not affected (peak 1). Moreover, epi-
nephrine, which did not produce loss of PKCα or PKCδ
activities in any peak, also did not induce dephosphorylation at
C-terminus (Fig. 5 panels B and C).
In order to investigate if the other posttranslational modi-
fications induced by PKC activators affect the catalytic ability,
Western blot analysis of PKCα and PKCδ immunoprecipitates
corresponding to each peak of activity was performed using
antibodies that recognize specifically the modifications. Results
shown in Fig. 5 panel D for PKCα and panel E for PKCδ
indicated that tyrosine phosphorylation increased in both PKC
709M. Robles-Flores et al. / Biochimica et Biophysica Acta 1783 (2008) 695–712isozymes when their activity were diminished as result of TPA
treatment (PKCα in peak 1 and PKCδ in peak 2, Fig. 5B)
whereas it decreased when the PKC activity was not affected or
even improved (PKCα in peak 2, Fig. 5B) with respect to
control. These results suggest therefore that tyrosine phosphor-
ylation may be negatively correlated with the activity of both
isozymes. With respect to Tyr nitration and O-GlcNAc modifi-
cations, it can be observed in Fig. 5 panel D that PKCα mod-
ified by these PTMs exhibited a clear inverse and negative
correlation with its activity, since both modifications induced
by TPA increased as activity decreased (PKCα obtained from
peak 1) whereas tyrosine nitration changes induced by TPA
decreased as PKCα activity improved (see PKCα activity in
peak 2 Fig. 5B). Modified PKCα correlate as well inversely with
the activity of this isozyme, increasing as a result of TPA
treatment of cells with concomitant inactivation of the enzyme
(PKCα in peak 1), and without affecting the activity when the O-
GlcNAc levels were unchanged (PKCα in peak 2), as it can be
observed in Fig. 5 panels B andD. Finally, data obtained with the
analysis of PKCδ showed that neither tyrosine nitration nor O-
GlcNAc modifications induced by TPA or epinephrine in this
isozyme could be correlated with the enzyme activity. Results in
Fig. 5 panels B and E show that TPA produced an augment in O-
GlcNAc content in PKCδ derived from both peaks 1 and 2,
which exhibited opposed catalytic ability (Fig. 5B). In the case
of tyrosine nitration, it was found that both TPA and epinephrine
produced a decrease in the level of this modification in PKCδ
derived from either peak 1 or peak 2, whose activities are
different (Fig. 5 panels B and E). Taken together, our data
suggest that while Ser/Thr phosphorylation at C terminus and
tyrosine phosphorylation status seem to regulate the activation
state of both PKCα and PKCδ isozymes, only PKCα activity
seems to be also regulated by tyrosine nitration and O-GlcNAc
posttranslational modifications.
4. Discussion
Data presented here indicate that posttranslational modifica-
tions (PTM) such as O-GlcNAc, tyrosine nitration and tyrosine
phosphorylation are commonly present in all PKC isozymes and
that they change rapidly and dynamically in response to
extracellular stimuli. With respect to the biochemical significance
in terms of PKC activity of the PTMs examined, results obtained
suggested that biochemical consequences of tyrosine nitration
and O-GlcNAc modifications may be different for each PKC
isozyme.However, they indicate that phosphorylation status, both
in Ser/Thr and in Tyr residues, may regulate the activity of all
PKC isozymes. In this respect, our data are in agreement with the
experimental evidence reported before for PKC. Posttranslational
modification of Ser/Thr residues by phosphorylation has been
recognized as an important mechanism modulating PKC activity
[2,14,15]. PKC is processed by three phosphorylation events
before it is competent to respond to second messengers.
Specifically, the enzyme is first phosphorylated at the activation
loop by another kinase (PDK-1), followed by two ordered
autophosphorylations at the carboxyl terminus, one on a ‘turn’
motif’ and the second on a conserved hydrophobic phosphory-lation motif [2,3]. These sites serve as phosphorylation regulated
switches to control maturation, signaling and down-regulation of
PKC. Without these priming phosphorylations the kinase is
catalytically-inactive. It has been reported that following TPA
stimulation of PKCα-transfected COS-7 cells, PKCα became
dephosphorylated at both the 497 and the 657 phosphorylation
sites. Moreover, the conversion of Ser 657 to alanine caused a
70% loss of the catalytic activity as well as a drastically increased
down-regulation upon translocation of this isozyme to the
membrane when induced by phorbol ester [15,16]. Consistent
with this, our data with PKCα andwith PKCδ indicate correlation
between the phosphorylation state at priming sites at the carboxyl
terminus and catalytic ability of both PKC isoforms. Whenever
TPA treatment provoked dephosphorylation of these sites, it
always produced catalytic inactivation of the enzyme. It is
remarkable that only TPA, but not epinephrine acting via α1-
adrenergic receptors, induced dephosphorylation of PKCα and δ.
We do not know the reason for this selectivity, but it is possible
that different signaling complexes are formed according with
which route of activation of one PKC isoform is used by the cell.
Thus, the different spatial organization of the enzyme within the
cell due to its association with adaptor proteins may play a role in
this selectivity. Also consistent with previous reports, our data
show that conventional and novel PKC isozymes were tyrosine
phosphorylated in response to phorbol ester or agonist treatment
of rat hepatocytes, indicating a complex mode of regulation
involving cross-talk between tyrosine kinases and other signaling
components [2,4]. Nishizuka and co-workers have demonstrated
that in response to H2O2, all PKC isoforms examined can be
activated to various extents through tyrosine phosphorylation
exhibiting independence of lipid cofactors [4]. However, in
several model systems, tyrosine phosphorylation is involved in
regulating PKCδ activity with resultant increase [17] or decrease
[18,19] in catalytic activity dependent on cell type and phos-
phorylation site. More detailed studies are needed to understand
fully the activation mechanisms of the PKC family involving
protein phosphorylation.
It was demonstrated here for the first time that all PKC
isozymes are dynamically modified by O-linked β-N-acetyl-
glucosamine (O-GlcNAc). In recent years, other signaling
components and many oncogene and tumor suppressor gene
products, such as c-Myc, SV40 large T antigen, and p53 were
also shown to be modified by O-GlcNAc. It has been reported
that O-GlcNAc levels change rapidly in response to extracel-
lular stress, extracellular stimuli, morphogens, the cell cycle and
development, which alludes to key roles for O-GlcNAc in
regulating cellular function [7,8]. However, the precise function
it plays on each protein remains unknown. Interestingly, O-
GlcNAc shares many common traits with O-phosphate. They
are both dynamic modifications processed by specific enzymes
that modify serine/threonine residues and rapidly respond to
extracellular stimuli. [20]. Notably, phosphorylation and O-
GlcNAc have been mapped to the same aminoacid on some well
studied proteins, which include the C-terminal domain of the
large subunit of RNA polymerase II, the c-myc proto-oncogene,
estrogen receptor β and endothelial nitric oxide synthase [20].
Consistent with this, the O-GlcNAc-modified Ser or Thr
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instances those residues predicted as YinO-Yang sites (see Table
2), and in the case of PKCε, it matched exactly with T710
located at ‘turn motif’ that it is known to be an autopho-
sphorylation ‘priming site’. In other instances, the modified
residue found did not match exactly with the predicted ones, but
were mapped near from the phosphorylation ‘priming sites’:
T517 in PKC epsilon, located just before the beginning of
‘activation loop’, T689 and S690, present at the end of‘hydrophobic motif’ of PKCγ , or S670, present at ‘turn
motif’ in PKC θ, just before the S676 ‘priming site’. Therefore,
these findings suggest that O-GlcNAc and phosphorylation may
modulate each other. Site-directed mutagenesis will give
valuable information about the functionality of all these
modified sites. However, it must be taken into account that
sometimes it has been obtained that mutation of one site results
in compensatory modification of adjacent residues. Indeed, in
the case of PKCβII, mutation of the turn motif residue results in
Fig. 5. Biochemicalmeaning studies of posttranslational modifications induced in PKCα and PKC δ enzymes. (A) Control in vitro phosphorylation studies with PKCα and
PKCδ. Phosphorylation of histoneH1-IIIS by PKCα or by PKCδ immune complexes (pooled fromDEAE-cellulose column eluates 1 and 2)was determined as described in
detail under Materials and methods in the absence or presence of the substrate histone H1 and in the absence or presence of 1 μM of the PKC-specific inhibitor
bisindolylmaleimide I. Reactions were allowed to proceed for 20min at 30 °C, ended by the addition of electrophoresis sample buffer, and analyzed by 10%SDS-PAGE and
autoradiography. A representative of three independent experiments is shown. The autoradiogram with its corresponding dried and Coomassie Blue-stained gel is shown.
Size markers are included at the left. (B) PKCα and PKCδ activities measured after treatment of cells with epinephrine or TPA. Histone phosphorylation by PKCα or by
PKCδ immune complexes obtained from either peak 1 or 2 eluates of DEAE-cellulose chromatography was measured in the presence of protein phosphatase inhibitors as
described underMaterials and methods. Autoradiograms and their corresponding stained gels were quantified with an image densitometer and the specific phosphorylation
was determined as the ratio of phosphorylated protein to the total protein content. Values plotted are means±S.E.M. for at least three experiments with different cell
preparations. (C–E) Comparative analysis of TPA or epinephrine-induced posttranslational modifications on PKCα and PKCδ. Freshly isolated rat hepatocytes were
incubated 5 min without (C), with 1 μMTPA (T), or with 10 μMepinephrine plus 10 μMpropranolol (E) at 37 °C; the cells were washed and PKC isozymes were partially
purified onDEAE-cellulose chromatography as described inMaterials andmethods. PKCwas eluted first with buffer containing 0.08MNaCl (peak 1) and thenwith 0.25M
NaCl (peak 2). PKCα or PKCδ was immunoprecipitated from each peak and immunoprecipitates analyzed by Western blotting for the presence of the posttranslational
modifications indicated in the figure. In each case, membranes were stripped and reprobed with the corresponding anti-PKC isozyme to demonstrate specificity and to serve
as loading control. The bar graphs show the quantitative scans of several independent experiments (change in PTM normalized to PKC protein and then expressed as % of
control or in arbitrary units). Values plotted are means±S.E.M. of at least four independent experiments using different cell preparations.
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functional kinase [21] and only mutation of both the turn motif
Thr and adjacent compensating sites abolishes kinase activity.With respect to PKC-tyrosine nitration, Knapp et al. reported in
2001 that brief incubation of either hippocampal homogenates or
purified PKC with peroxynitrite (ONOO−) inhibited cofactor-
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nitration of Tyr residues on PKC [22]. Balafanova et al. have
demonstrated that posttranslational modification of PKCε by nitric
oxide (NO) donors, namely nitration of PKCε, facilitates its
translocation and activation in vivo in the rabbit myocardium
preconditioned with NO donors [6]. It has been reported that
several reactions mediate protein nitration, and all predominantly
depend on ·NO and nitrite-dependent formation of nitrogen diox-
ide, a species capable of nitrating aromatic aminoacids, nucleotides
and unsaturated fatty acids [5]. In this work, we have found that
TPA or epinephrine-stimulated rat hepatocytes underwent a rapid
change in PKC tyrosine nitration content. Although we do not
know the precise mechanism underlying this PKC nitration, our
data are consistent with the notion that protein nitration depend on
nitric oxide (·NO) formation. We showed here that MEG, a
selective cell permeable inhibitor of inducible nitric oxide synthase
(iNOS), was able to abolish the increase in tyrosine nitration
induced in PKCα by TPA (see Fig. 2 panel D). In this regard, it is
well known that TPA has been involved in the activation of several
potential catalysts of ONOO−-mediated tyrosine nitration in tissues
such as peroxidases, metalloproteins and superoxide dismutases
[5]. In addition, it has been reported that epinephrine produced NO
at significant levels in a dose-dependent manner in porcine
trabecular meshwork cells in vitro [23] and that injection of
corticotropin-releasing factor into the brain ventricles releases
catecholamines and stimulate NO production [24].
Taken together, the experimental evidence presented here
indicate that posttranslational modifications are essential devi-
ces to influence PKC actions. They may regulate PKC either
directly influencing its catalytic abilities or by other means such
as regulating the interaction capabilities of the kinase with other
proteins and/or influencing its intracellular localization. In this
way, posttranslational modifications may generate tremendous
diversity, complexity and heterogeneity of gene products and
their determination is one of the main challenges in proteomics
and signal transduction research.
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